Lipella pharmaceuticals granted fda approval for expanded access program for lp-310 in oral lichen planus

Pittsburgh, february 6, 2025 – prism mediawire – lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the u.s.
LIPO Ratings Summary
LIPO Quant Ranking